Stock Information

As of November 2, 2026, Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc. have successfully completed their merger of equals transaction, creating a leading diversified central nervous system (CNS) biopharmaceutical company with a broad portfolio of marketed medicines, a differentiated pipeline, financial flexibility and the capacity to pursue growth opportunities. The combined company will now operate as Supernus, Inc. and will continue trading on the Nasdaq Global Select Market. The combined company shares will begin trading under the ticker symbol "SUPN" on November 3, 2026.

Supernus Pharmaceuticals, Inc. will now be a wholly owned subsidiary of Supernus, Inc., formerly known as Indivior Pharmaceuticals, Inc.

Stock Quote (SUPN)

Change
Volume
Today's Open
Previous Close
Today's High
Today's Low
52 Week High
52 Week Low

Stock Chart

Minimum 15 minutes delayed. Source: LSEG